Abstract
Consumption of probiotic products continues to increase, perhaps driven by an interest in gut health. However, the field is filled with controversy, inconsistencies, misuse of terminology, and poor communication. While the probiotic concept is biologically plausible and in some cases mechanistically well established, extrapolation of preclinical results to humans has seldom been proven in well-conducted clinical trials. With noteworthy exceptions, clinical guidance has often been derived not from large, adequately powered clinical trials but rather from comparisons of disparate, small studies with insufficient power to identify the optimal strain. The separation of probiotics from live biotherapeutic products has brought some clarity from a regulatory perspective, but in both cases, consumers should expect scientific rigor and strong supporting evidence for health claims.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 129-141 |
| Number of pages | 13 |
| Journal | Annual Review of Medicine |
| Volume | 76 |
| DOIs | |
| State | Published - Jan 27 2025 |
Keywords
- antibiotic-associated diarrhea
- clinical trials
- Clostridioides difficile–associated disease
- microbiome
- necrotizing enterocolitis
- probiotics
- Probiotics/therapeutic use
- Humans
- Gastrointestinal Microbiome/physiology
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology
Divisions
- Gastroenterology and Hepatology
Fingerprint
Dive into the research topics of 'Probiotics in Health Care: A Critical Appraisal'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS